ERAEnvironmental Risk Assessment
For human medicinal products, the current EMA guideline describes a stepwise assessment of potential environmental risks arising from product use. It considers the active substance's use, physicochemical properties, fate and ecotoxicity, with risk and hazard assessment including PBT/vPvB considerations.
- Phase I exposure screening and PECSW assessment
- Phase II fate, effects and risk characterisation where required
- PBT/vPvB and tailored assessment strategies for relevant substance groups
- EU / UK submission-context review
Read the ERA background →
PDEPDE / ADE
A health-based exposure limit is a substance-specific threshold derived from pharmacological and toxicological evidence. The EMA HBEL guideline describes PDE as a dose unlikely to cause an adverse effect when exposure is at or below that level every day over a lifetime.
- Hazard and critical-effect review
- Point-of-departure and adjustment-factor evaluation
- Route-to-route considerations where relevant
- Cleaning / shared-facility carryover context
Read the PDE / ADE background →
OELOEL / OEB / OHC
Occupational exposure limits are workplace airborne concentration limits used to help control worker exposure. Depending on the applicable framework, limits can be expressed as time-weighted averages, short-term limits or ceiling values. Exposure banding can be used when a numeric OEL is unavailable or as part of a broader control strategy. In pharmaceutical settings, OHC (Occupational Hazard Category) and OEB (Occupational Exposure Band) terminology may be used; band definitions and cut-offs are organisation-dependent.
- Health-based OEL derivation
- OEB / OHC banding support
- Exposure and route considerations
- Industrial-hygiene context and control strategy support
Read the OEL / OEB background →